AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. CTXR
  4. [Form 4] Citius Pharmaceuticals Inc. Common Insider Trading Activity

[Form 4] Citius Pharmaceuticals Inc. Common Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Myron Z. Holubiak, Vice Chairman and a director of Citius Pharmaceuticals (CTXR), reported the disposition of 79,690 shares of common stock and amendments to two outstanding warrants on 08/08/2025. The warrant amendments cancelled the prior warrants and granted replacement warrants exercisable into 31,373 and 22,344 shares, each extended by one year.

The filing lists multiple stock options and warrants remaining beneficially owned by the reporting person, including direct options exercisable into a total of 107,667 common shares and warrants covering 53,717 common shares. Certain options are held indirectly by the reporting person鈥檚 daughter and are disclaimed. All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.

Myron Z. Holubiak, vicepresidente e amministratore di Citius Pharmaceuticals (CTXR), ha segnalato la cessione di 79,690 azioni ordinarie e le modifiche a due warrant in scadenza il 08/08/2025. Le modifiche ai warrant hanno annullato i warrant precedenti e hanno concesso warrant sostitutivi esercitabili in 31,373 e 22,344 azioni, ciascuno prorogato di un anno.

La comunicazione elenca diverse opzioni su azioni e warrant che rimangono di propriet脿 beneficiaria della persona che segnala, incluse opzioni dirette esercitabili in un totale di 107,667 azioni ordinarie e warrant relativi a 53,717 azioni ordinarie. Alcune opzioni sono detenute indirettamente dalla figlia della persona segnalante e sono state dichiarate come rinunciate. Tutti gli importi azionari riflettono lo split inverso 1-per-25 entrato in vigore il 22 novembre 2024.

Myron Z. Holubiak, vicepresidente y director de Citius Pharmaceuticals (CTXR), inform贸 la enajenaci贸n de 79,690 acciones ordinarias y las enmiendas a dos warrants pendientes el 08/08/2025. Las enmiendas a los warrants cancelaron los warrants anteriores y concedieron warrants de reemplazo ejercitables en 31,373 y 22,344 acciones, cada uno ampliado por un a帽o.

El registro enumera varias opciones sobre acciones y warrants que la persona declarante contin煤a poseyendo de forma beneficiaria, incluidas opciones directas ejercitables en un total de 107,667 acciones ordinarias y warrants que cubren 53,717 acciones ordinarias. Ciertas opciones est谩n en poder indirecto de la hija de la persona declarante y han sido renunciadas por el declarante. Todos los montos de acciones reflejan la divisi贸n inversa de acciones 1-por-25 con vigencia el 22 de noviembre de 2024.

Myron Z. Holubiak鞚� Citius Pharmaceuticals(CTXR)鞚� 攵�須岇灔鞚挫瀽 鞚挫偓搿滌劀 2025雲� 8鞗� 8鞚� 氤错喌欤� 79,690欤� 觳橂秳 氚� 霊� 瓯挫潣 氙戈舶 鞗岆煱韸胳棎 雽�頃� 靾橃爼靷暛鞚� 鞁犼碃頄堨姷雼堧嫟. 鞗岆煱韸� 靾橃爼鞙茧 旮办〈 鞗岆煱韸鸽姅 旆唽霅橃棃瓿�, 臧侁皝 31,373欤� 氚� 22,344欤茧 頄夓偓 臧�電ロ暅 雽�觳� 鞗岆煱韸戈皜 攵�鞐悩鞐堨溂氅�, 臧� 鞗岆煱韸胳潣 毵岅赴臧� 1雲� 鞐办灔霅橃棃鞀惦媹雼�.

鞁犼碃靹滌棎電� 頃措嫻 鞁犼碃鞚胳澊 瓿勳啀頃挫劀 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 鞐煬 欤检嫕鞓奠厴瓿� 鞗岆煱韸戈皜 旮办灛霅橃柎 鞛堨溂氅�, 歆侅爲 氤挫湢霅� 鞓奠厴鞚� 齑� 107,667 氤错喌欤茧 頄夓偓 臧�電ロ晿瓿� 鞗岆煱韸鸽姅 53,717 氤错喌欤茧ゼ 旎る矂頃╇媹雼�. 鞚茧秬 鞓奠厴鞚� 鞁犼碃鞚胳潣 霐� 氇呾潣搿� 臧勳爲 氤挫湢霅橃柎 鞛堨溂氅� 鞁犼碃鞚胳澊 甓岆Μ 韽赴毳� 靹犾柛頄堨姷雼堧嫟. 氇摖 欤检嫕 靾橃箻電� 2024雲� 11鞗� 22鞚茧秬搿� 須牓 氚滌儩頃� 1雽�25 鞐秳頃犾潉 氚橃榿頃╇媹雼�.

Myron Z. Holubiak, vice-pr茅sident et administrateur de Citius Pharmaceuticals (CTXR), a d茅clar茅 la cession de 79,690 actions ordinaires et les modifications apport茅es 脿 deux warrants en cours le 08/08/2025. Les modifications ont annul茅 les warrants ant茅rieurs et accord茅 des warrants de remplacement exer莽ables en 31,373 et 22,344 actions, chacun prorog茅 d'un an.

Le dossier 茅num猫re plusieurs options d'achat d'actions et warrants qui restent d茅tenus 脿 titre b茅n茅ficiaire par la personne d茅clarante, y compris des options directes exer莽ables pour un total de 107,667 actions ordinaires et des warrants couvrant 53,717 actions ordinaires. Certaines options sont d茅tenues indirectement par la fille de la personne d茅clarante et ont 茅t茅 d茅clar茅es renonc茅es. Tous les montants d'actions refl猫tent le regroupement d'actions inverse 1-pour-25 effectif le 22 novembre 2024.

Myron Z. Holubiak, stellvertretender Vorsitzender und Direktor von Citius Pharmaceuticals (CTXR), meldete am 08/08/2025 die Ver盲u脽erung von 79,690 Stammaktien sowie 脛nderungen an zwei ausstehenden Warrants. Die 脛nderungen hoben die vorherigen Warrants auf und gew盲hrten Ersatzwarrants, die in 31,373 bzw. 22,344 Aktien aus眉bbar sind und jeweils um ein Jahr verl盲ngert wurden.

Die Einreichung listet mehrere Aktienoptionen und Warrants auf, die weiterhin wirtschaftlich im Besitz der meldenden Person verbleiben, darunter direkte Optionen, die insgesamt in 107,667 Stammaktien aus眉bbar sind, sowie Warrants 眉ber 53,717 Stammaktien. Bestimmte Optionen werden indirekt im Namen der Tochter der meldenden Person gehalten und vom Melder als nicht beansprucht (disclaimed) angegeben. Alle Aktienangaben spiegeln den zum 22. November 2024 wirksamen Reverse-Split 1-zu-25 wider.

Positive
  • Retains substantial derivative positions: direct stock options exercisable into 107,667 shares and replacement warrants covering 53,717 shares
  • Several options are vested and exercisable immediately, preserving potential alignment with long-term shareholder value
Negative
  • Disposition of 79,690 common shares reported, representing insider selling of company stock
  • Two warrants were amended to extend termination dates by one year, replacing old warrants and potentially delaying exercise-related proceeds

Insights

TL;DR: Insider sold 79,690 shares and had two warrants amended, while retaining significant options and warrants exposure.

The disposal of 79,690 common shares is a clear, reportable insider sale and reduces the reporting person鈥檚 direct common-stock holdings. Concurrently, the reporting person鈥檚 existing warrants were amended鈥攐ld instruments cancelled and replacement warrants granted鈥攅xtending exercise windows by one year for instruments covering 31,373 and 22,344 shares. The filing also shows substantial derivative exposure, with direct options exercisable into 107,667 shares and replacement warrants covering 53,717 shares. For analysts, the combination of a direct sale and continued large derivative positions is a mixed signal: near-term liquidity has been realized while long-term upside via options/warrants remains intact.

TL;DR: Director/officer reported routine Section 16 activity: a significant disposition plus warrant amendments and notable retained equity incentives.

The filer is identified as both a director and Vice Chairman, making these transactions material under insider-reporting rules. The warrant amendments replaced expiring instruments with new warrants, shifting potential dilutive events forward by one year. Several stock options are noted as vested and exercisable immediately, while a subset of options is held indirectly by a family member and explicitly disclaimed. The filing properly discloses the changes and the reverse-split adjustment; governance committees will likely note the insider sale and the extended warrant exercise timeline when assessing executive equity alignment.

Myron Z. Holubiak, vicepresidente e amministratore di Citius Pharmaceuticals (CTXR), ha segnalato la cessione di 79,690 azioni ordinarie e le modifiche a due warrant in scadenza il 08/08/2025. Le modifiche ai warrant hanno annullato i warrant precedenti e hanno concesso warrant sostitutivi esercitabili in 31,373 e 22,344 azioni, ciascuno prorogato di un anno.

La comunicazione elenca diverse opzioni su azioni e warrant che rimangono di propriet脿 beneficiaria della persona che segnala, incluse opzioni dirette esercitabili in un totale di 107,667 azioni ordinarie e warrant relativi a 53,717 azioni ordinarie. Alcune opzioni sono detenute indirettamente dalla figlia della persona segnalante e sono state dichiarate come rinunciate. Tutti gli importi azionari riflettono lo split inverso 1-per-25 entrato in vigore il 22 novembre 2024.

Myron Z. Holubiak, vicepresidente y director de Citius Pharmaceuticals (CTXR), inform贸 la enajenaci贸n de 79,690 acciones ordinarias y las enmiendas a dos warrants pendientes el 08/08/2025. Las enmiendas a los warrants cancelaron los warrants anteriores y concedieron warrants de reemplazo ejercitables en 31,373 y 22,344 acciones, cada uno ampliado por un a帽o.

El registro enumera varias opciones sobre acciones y warrants que la persona declarante contin煤a poseyendo de forma beneficiaria, incluidas opciones directas ejercitables en un total de 107,667 acciones ordinarias y warrants que cubren 53,717 acciones ordinarias. Ciertas opciones est谩n en poder indirecto de la hija de la persona declarante y han sido renunciadas por el declarante. Todos los montos de acciones reflejan la divisi贸n inversa de acciones 1-por-25 con vigencia el 22 de noviembre de 2024.

Myron Z. Holubiak鞚� Citius Pharmaceuticals(CTXR)鞚� 攵�須岇灔鞚挫瀽 鞚挫偓搿滌劀 2025雲� 8鞗� 8鞚� 氤错喌欤� 79,690欤� 觳橂秳 氚� 霊� 瓯挫潣 氙戈舶 鞗岆煱韸胳棎 雽�頃� 靾橃爼靷暛鞚� 鞁犼碃頄堨姷雼堧嫟. 鞗岆煱韸� 靾橃爼鞙茧 旮办〈 鞗岆煱韸鸽姅 旆唽霅橃棃瓿�, 臧侁皝 31,373欤� 氚� 22,344欤茧 頄夓偓 臧�電ロ暅 雽�觳� 鞗岆煱韸戈皜 攵�鞐悩鞐堨溂氅�, 臧� 鞗岆煱韸胳潣 毵岅赴臧� 1雲� 鞐办灔霅橃棃鞀惦媹雼�.

鞁犼碃靹滌棎電� 頃措嫻 鞁犼碃鞚胳澊 瓿勳啀頃挫劀 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 鞐煬 欤检嫕鞓奠厴瓿� 鞗岆煱韸戈皜 旮办灛霅橃柎 鞛堨溂氅�, 歆侅爲 氤挫湢霅� 鞓奠厴鞚� 齑� 107,667 氤错喌欤茧 頄夓偓 臧�電ロ晿瓿� 鞗岆煱韸鸽姅 53,717 氤错喌欤茧ゼ 旎る矂頃╇媹雼�. 鞚茧秬 鞓奠厴鞚� 鞁犼碃鞚胳潣 霐� 氇呾潣搿� 臧勳爲 氤挫湢霅橃柎 鞛堨溂氅� 鞁犼碃鞚胳澊 甓岆Μ 韽赴毳� 靹犾柛頄堨姷雼堧嫟. 氇摖 欤检嫕 靾橃箻電� 2024雲� 11鞗� 22鞚茧秬搿� 須牓 氚滌儩頃� 1雽�25 鞐秳頃犾潉 氚橃榿頃╇媹雼�.

Myron Z. Holubiak, vice-pr茅sident et administrateur de Citius Pharmaceuticals (CTXR), a d茅clar茅 la cession de 79,690 actions ordinaires et les modifications apport茅es 脿 deux warrants en cours le 08/08/2025. Les modifications ont annul茅 les warrants ant茅rieurs et accord茅 des warrants de remplacement exer莽ables en 31,373 et 22,344 actions, chacun prorog茅 d'un an.

Le dossier 茅num猫re plusieurs options d'achat d'actions et warrants qui restent d茅tenus 脿 titre b茅n茅ficiaire par la personne d茅clarante, y compris des options directes exer莽ables pour un total de 107,667 actions ordinaires et des warrants couvrant 53,717 actions ordinaires. Certaines options sont d茅tenues indirectement par la fille de la personne d茅clarante et ont 茅t茅 d茅clar茅es renonc茅es. Tous les montants d'actions refl猫tent le regroupement d'actions inverse 1-pour-25 effectif le 22 novembre 2024.

Myron Z. Holubiak, stellvertretender Vorsitzender und Direktor von Citius Pharmaceuticals (CTXR), meldete am 08/08/2025 die Ver盲u脽erung von 79,690 Stammaktien sowie 脛nderungen an zwei ausstehenden Warrants. Die 脛nderungen hoben die vorherigen Warrants auf und gew盲hrten Ersatzwarrants, die in 31,373 bzw. 22,344 Aktien aus眉bbar sind und jeweils um ein Jahr verl盲ngert wurden.

Die Einreichung listet mehrere Aktienoptionen und Warrants auf, die weiterhin wirtschaftlich im Besitz der meldenden Person verbleiben, darunter direkte Optionen, die insgesamt in 107,667 Stammaktien aus眉bbar sind, sowie Warrants 眉ber 53,717 Stammaktien. Bestimmte Optionen werden indirekt im Namen der Tochter der meldenden Person gehalten und vom Melder als nicht beansprucht (disclaimed) angegeben. Alle Aktienangaben spiegeln den zum 22. November 2024 wirksamen Reverse-Split 1-zu-25 wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HOLUBIAK MYRON Z
(Last) (First) (Middle)
C/O CITIUS PHARMACEUTICALS, INC.
11 COMMERCE DRIVE, 1ST FLOOR
(Street)
CRANFORD NJ 07016
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Citius Pharmaceuticals, Inc. [ CTXR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Vice Chairman
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 79,690 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to Purchase Common Stock(1) $28.75 08/08/2025 D(1) 31,373 (1) 08/14/2025 Common Stock 31,373 (1) 0 D
Warrant to Purchase Common Stock(1) $28.75 08/08/2025 A(1) 31,373 (1) 08/14/2026 Common Stock 31,373 (1) 31,373 D
Warrant to Purchase Common Stock(2) $19.25 08/08/2025 D(2) 22,344 (2) 09/27/2025 Common Stock 22,344 (2) 0 D
Warrant to Purchase Common Stock(4) $19.25 08/08/2025 A(2) 22,344 (2) 09/27/2026 Common Stock 22,344 (2) 22,344 D
Stock Option (Right to Purchase Common Stock) $9.5 (3) 11/07/2034 Common Stock 14,000 14,000 D
Stock Option (Right to Buy) $9.5 (4) 11/07/2034 Common Stock 3,000 3,000 I See footnote(4)
Stock Option (Right to Purchase Common Stock) $17.5 (5) 10/10/2033 Common Stock 16,000 16,000 D
Stock Option (Right to Purchase Common Stock) $31.25 (6) 10/04/2032 Common Stock 16,000 16,000 D
Stock Option (Right to Purchase Common Stock) $51 (7) 10/11/2031 Common Stock 26,000 26,000 D
Stock Option (Right to Purchase Common Stock) $51 (4) 10/11/2031 Common Stock 600 600 I See footnote(4)
Stock Option (Right to Purchase Common Stock) $50 (7) 07/22/2031 Common Stock 12,000 12,000 D
Stock Option (Right to Purchase Common Stock) $50 (4) 07/22/2031 Common Stock 400 400 I See footnote(4)
Stock Option (Right to Purchase Common Stock) $25.25 (7) 10/06/2030 Common Stock 8,000 8,000 D
Stock Option (Right to Purchase Common Stock) $16.75 (7) 10/08/2029 Common Stock 7,000 7,000 D
Stock Option (Right to Purchase Common Stock) $40.5 (7) 09/04/2028 Common Stock 6,000 6,000 D
Stock Option (Right to Purchase Common Stock) $86.25 (7) 09/13/2027 Common Stock 1,600 1,600 D
Stock Option (Right to Purchase Common Stock) $202.5 (7) 10/01/2025 Common Stock 1,067 1,067 D
Explanation of Responses:
1. The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.
2. The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.
3. The options were granted on November 7, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
4. The options are held by the Reporting Person's daughter. The Reporting Person disclaims beneficial ownership in these shares.
5. The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
6. The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
7. The options are vested in full and exercisable immediately.
Remarks:
All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.
/s/ Alexander M. Donaldson, by power of attorney 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did CTXR insider Myron Holubiak report on Form 4?

He reported a disposition of 79,690 common shares, amendments cancelling two existing warrants and granting replacement warrants exercisable into 31,373 and 22,344 shares, and disclosed multiple stock options.

How many shares were disposed of by the reporting person (CTXR)?

The Form 4 shows a disposition of 79,690 shares of common stock.

What changed with the warrants in the filing?

Two outstanding warrants were amended: the 31,373-share warrant (originally issued August 13, 2018) and the 22,344-share warrant (originally issued September 27, 2019) were cancelled and replaced with new warrants extended by one year (new expirations August 14, 2026 and September 27, 2026).

How many option shares does the reporting person directly control?

The filing lists direct stock options exercisable into a total of 107,667 common shares across various strike prices and expiration dates.

Does the reporting person disclaim any beneficial ownership?

Yes. A subset of options (for example 3,000, 600, and 400 option shares) are held by the reporting person鈥檚 daughter and the reporting person disclaims beneficial ownership of those shares.

Are share amounts adjusted for any corporate actions?

Yes. The Form notes that all share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.
Stock CTXR logo
Citius Pharmaceuticals Inc

NASDAQ:CTXR

CTXR Rankings

#5858 Ranked by Market Cap
N/A Ranked by Dividends

CTXR Latest News

Aug 12, 2025
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Jul 17, 2025
Citius Oncology Announces Closing of $9.0 Million Public Offering
Jul 16, 2025
Citius Oncology Announces Pricing of $9.0 Million Public Offering
Jul 15, 2025
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Jul 8, 2025
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

CTXR Latest SEC Filings

Aug 12, 2025
[8-K] Citius Pharmaceuticals Inc. Common Reports Material Event
Aug 12, 2025
[10-Q] Citius Pharmaceuticals Inc. Common Quarterly Earnings Report
Jul 8, 2025
[8-K] Citius Pharmaceuticals Inc. Common Reports Material Event

CTXR Stock Data

13.74M
10.68M
4.41%
7.33%
10.04%
Biotechnology
Pharmaceutical Preparations
United States
CRANFORD